Merck is counting on the lung disease treatment Winrevair and other new medicines to offset the impending decline of Keytruda. It's also betting on novel treatments for obesity and cardiovascular disease. Merck expects final-stage results later this year from a study on a pill designed to dramatically lower bad cholesterol, and it has signed deals worth up to $4 billion for the rights to others in the early stages of development for weight loss and heart disease. For the full year, adjusted earnings will be between $8.82 per share and $8.97 per share, the Rahway, New Jersey-based company said in a statement Thursday, reduced by 6 cents to account for a recent licensing deal. Merck maintained its full-year sales projection of $64.1 billion to $65.6 billion.